InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$254.06

2026-10-16

Market Cap

$58.8B

Volume

1.3M

52-Wk High

$258.30

52-Wk Low

$152.46

Trailing PE

34.9

P/S

0.23

Gross Margin

3.8%

Net Margin

0.7%

ROE

-60%

ROIC

13%

Piotroski

7/9

Altman Z

5.1

1-Yr Return

+67.3%

5-Yr Return

+599.3%

Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.

SectorHealthcareIndustryMedical - DistributionExchangeNYSEMarket Cap$58.8BEmployees63,900 (SEC-filed)CEOJason HollarIPO1983-08-04CountryUS

7000 Cardinal Place, Dublin, OH 43017 · Tel 614 757 5000 · cardinalhealth.com

INSIDERSTREET SCORE59 / 100Street mean $275.27 (11 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$60M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · CAH +67.3% · S&P 500 +15.9% · spread +51.4pp

7 Years vs S&P 500 · CAH +599.3% · S&P 500 +189.9% · spread +409.4pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE59of 100

Score Breakdown

Profitability	6/100
Growth	68/100
Momentum	84/100
Quality	57/100
Earnings Quality	82/100
Balance Sheet	42/100
Value	41/100
Risk (safety)	100/100
Overall	58.6/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
ABC	61
MCK	60
HSIC	51
NTRA	50
BSX	67
BDX	43
CAH	59

IS Score Trend — quarterly

16 quarters, 23 Q1 to 26 Q4. Peak 62 in 23 Q3, latest 59 — -4 since. Fell in 2 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY59 / 100IS Score 58.6 / 100 · -3.6 from peak of 62

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 88 / 100 · Power +75 · 21 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 59 and price structure at 88 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 58.6	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 59 → 58 → 55 → 59	the direction matters more than the level
Technical vote share back above 50%	now 100%	price structure no longer broken
Institutional holder count rises two quarters running	peak 1,497 → now 1,497	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)1 buys2026-03-27

Insider Buys (180d)0none disclosed

ETF Funds (30d)1222 up / 1078 downnet +144 funds

Institutions Added (13F)66managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 1,497 · latest 1,497 (+0 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	1,497	208.4M	$47.9B	88.3%
2026 Q1	1,431	202.2M	$41.2B	85.7%
2025 Q4	1,407	208.2M	$41.5B	88.2%
2025 Q3	1,219	207.0M	$31.7B	87.7%
2025 Q2	1,249	205.5M	$33.8B	87.1%
2025 Q1	1,148	207.8M	$28.0B	88.0%
2024 Q4	1,093	210.3M	$24.4B	89.1%
2024 Q3	1,010	211.3M	$23.1B	89.5%
2024 Q2	1,004	213.6M	$20.2B	90.5%
2024 Q1	1,054	217.5M	$23.2B	92.2%
2023 Q4	1,030	212.6M	$20.4B	90.1%
2023 Q3	944	215.0M	$17.8B	91.1%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Hollar Jason M.	Chief Executive Officer	2026-08-19	SELL	6,206	$1.45M	228,926
Hollar Jason M.	Chief Executive Officer	2026-08-19	SELL	3,457	$0.81M	225,469
Hollar Jason M.	Chief Executive Officer	2026-08-19	SELL	5,704	$1.34M	219,765
Hollar Jason M.	Chief Executive Officer	2026-08-19	SELL	6,731	$1.59M	213,034
Hollar Jason M.	Chief Executive Officer	2026-08-19	SELL	16,187	$3.84M	196,847
Hollar Jason M.	Chief Executive Officer	2026-08-19	SELL	6,244	$1.49M	190,603
Scherer Mary C.	Chief Accounting Officer	2026-08-19	SELL	100	$0.02M	5,013
Scherer Mary C.	Chief Accounting Officer	2026-08-19	SELL	2,202	$0.52M	2,811

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	33	255,017	$60.2M	Counted
F — Tax withholding	8	228,152	$53.7M	None — compensation
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$60.2M33 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-08-19	Mary Scherer	2,302	$0.5M
2026-08-18	Aaron Alt	42,000	$9.9M
2026-08-18	Deborah Weitzman	7,354	$1.7M
2026-08-18	Jessica Mayer	29,436	$7.0M
Trailing 12 mo	11 filings	304,887	$70M

Filed	Form	Reporting person	% of class	Shares
2026-04-29	SCHEDULE 13G	Vanguard Portfolio Management	5.85%	13.8M sh
2026-04-29	SCHEDULE 13G	Vanguard Capital Management	7.49%	17.6M sh
2026-03-26	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change
2026-01-21	SCHEDULE 13G/A	BlackRock Portfolio Management LLC	3.80%	9.1M sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Marjorie Taylor Greene	House	BUY	$1,001 - $15,000	2025-10-24	2025-10-29
Marjorie Taylor Greene	House	BUY	$1,001 - $15,000	2025-10-23	2025-10-29
Ro Khanna	House	SELL	$1,001 - $15,000	2025-09-05	2025-10-03
Alan Armstrong	Senate	BUY	$1,001 - $15,000	2026-03-27	2026-07-20
Kelly Loeffler	Senate	SELL	$100,001 - $250,000	2020-04-07	2020-05-01
Kelly Loeffler	Senate	BUY	$1,001 - $15,000	2020-04-07	2020-05-01

House 12-Mo3 trades2 purchases

Senate 12-Mo1 trades1 purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)1,431

13F Shares202M85.7% of shares out

New / Closed158 / 106positions, QoQ

Increased / Reduced564 / 505positions, QoQ

Put/Call (13F)1.04option positions

Free Float99.8%231M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Artemis Investment Management Llp	343,092	$76M
Wedge Capital Management L L P/Nc	113,456	$25M
Fjarde Ap-Fonden /Fourth Swedish N	108,754	$24M
Kwmg, Llc	73,433	$16M
Mn Services Vermogensbeheer B.V.	68,725	$15M
Czech National Bank	66,825	$15M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.1%	$1.6B
VTI	0.1%	$1.6B
VTSAX	0.1%	$1.6B
VSMPX	0.1%	$1.6B
VFIAX	0.1%	$1.4B
VOO	0.1%	$1.4B

13F Filers Holding CAH — quarterly

Institutional Put/Call — quarterly

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session47.8%2026-10-15

20-Day Avg50.3%50-day 49.1%

TrendRising20d vs 50d

By Market CenterQ: 46% · N: 60% · B: 83%latest session

Weekly Notional ($B)

Where CAH Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	1.7M	29 sh
Ubsa Ubs Ats	1.4M	36 sh
Sgmt Sigma X2	1.0M	29 sh
Ebxl Level Ats	0.9M	17 sh
Mlix Instinct X	0.9M	45 sh
Mspl Ms Pool (Ats-4)	0.8M	142 sh

Where a dollar of Cardinal Health, Inc. revenue goes. All values FY2026 filings, live.

Region	Revenue	Share
UNITED STATES	$252.6B	99%
Non-US	$1.7B	1%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

CAH (live moat model)Peer median: ABC · MCK · HSIC · NTRA · BSX

Component scores from the live moat model. Peer median illustrative.

Moat score 55/100 — Narrow; primary source Efficient Scale.

3.8 · Employees (SEC filings)

Officer	Title
Jason Hollar	Chief Executive Officer & Director
Aaron E. Alt	Chief Financial Officer
Deborah L. Weitzman	Chief Executive Officer of Pharmaceutical & Specialty Solutions Segment
Jessica L. Mayer	Chief Legal & Compliance Officer

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)5 of 6recent quarters

Avg Surprise+12.2%

Next Report2026-11-05

Income Quality3.03OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY22	FY23	FY24	FY25	FY26
Revenue	+11.6%	+13.0%	+10.7%	-1.9%	+14.2%
Gross profit	-4.3%	+6.2%	+7.6%	+10.2%	+19.7%
Operating income	-228.6%	-223.9%	+65.3%	+83.0%	+14.9%
Net income	-253.5%	-135.2%	+158.2%	+83.2%	+9.8%

$B · FY ends	FY22	FY23	FY24	FY25	FY26
Revenue	181.3	205.0	226.8	222.6	254.2
Cost of revenue	174.8	198.1	219.4	214.4	244.5
Gross profit	6.5	6.9	7.4	8.2	9.8
R&D expense	0.0	0.0	0.0	0.0	0.0
SG&A expense	4.5	4.8	5.0	5.4	6.1
Operating income	-0.6	0.8	1.2	2.3	2.6
EBITDA	0.1	1.4	2.0	3.1	3.5
D&A	0.7	0.7	0.7	0.8	1.0
Pretax income	-0.8	0.7	1.2	2.1	2.2
Income tax	0.2	0.3	0.3	0.5	0.5
Net income	-0.9	0.3	0.9	1.6	1.7
Diluted EPS ($)	-3.34	1.26	3.45	6.45	7.23
Diluted shares (M)	279	262	247	242	237

Operating CF$5B

CapEx$1B

Free cash flow$5B

SBC$0B

Buybacks$1B

Net cash change$1B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY23	FY24	FY25	FY26
Cash & equivalents	4.1	5.1	3.9	4.9
ST investments	0.0	0.0	0.0	0.0
Receivables (net)	11.1	12.1	13.2	13.8
Total current assets	33.7	34.9	36.4	38.8
PP&E (net)	2.5	2.5	2.9	4.0
Goodwill + intangibles	6.1	6.5	12.2	13.6
Total assets	43.3	45.1	53.1	57.3
Accounts payable	29.9	31.8	34.7	38.3
Short-term debt	0.9	0.6	0.7	1.8
Deferred revenue	0.0	0.0	0.0	0.0
Total current liabilities	33.7	35.6	38.9	43.9
Long-term debt	3.9	4.6	7.8	6.9
Total liabilities	46.3	48.3	55.8	60.0
Shareholders' equity	-3.0	-3.2	-2.6	-2.7

Cash Flow Statement — Full

$B	FY23	FY24	FY25	FY26
Net income	0.3	0.9	1.6	1.7
D&A	0.7	0.7	0.8	1.0
Stock-based compensation	0.1	0.1	0.2	0.4
Working capital change	0.5	1.5	(0.5)	2.1
Operating cash flow	2.8	3.8	2.4	5.2
Capital expenditures	(0.5)	(0.5)	(0.5)	(0.6)
Investing cash flow	(0.5)	(1.8)	(5.6)	(2.6)
Buybacks	(2.0)	(0.8)	(0.8)	(1.4)
Dividends paid	(0.5)	(0.5)	(0.5)	(0.5)
Debt issuance / (repay)	(0.6)	0.4	3.2	0.3
Financing cash flow	(3.1)	(0.8)	2.0	(1.6)
Free cash flow	2.4	3.3	1.9	4.5

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY22	FY23	FY24	FY25	FY26	TTM
PROFITABILITY
ROE	-172.3%	-14.2%	-27.6%	-52.1%	-60.5%	-60%
ROA	-2.1%	0.6%	1.9%	3.2%	3.1%	3.0%
ROIC	-124.2%	-16.1%	-32.3%	63.2%	92.8%	13.2%
Gross margin	3.6%	3.4%	3.3%	3.7%	3.8%	3.8%
Operating margin	-0.3%	0.4%	0.5%	1.0%	1.0%	1.0%
Net margin	-0.5%	0.2%	0.4%	0.7%	0.7%	0.7%
EBITDA margin	0.0%	0.7%	0.9%	1.4%	1.4%	1.4%
FCF margin	1.5%	1.2%	1.4%	0.8%	1.8%	—
VALUATION
P/E	-14.45	88.49	27.57	25.67	32.78	34.9
P/B	-19.00	-7.81	-7.32	-14.41	-19.49	-20.8
P/S	0.07	0.11	0.10	0.18	0.22	0.23
P/FCF	4.92	9.79	7.25	21.66	12.42	13.0
EV/EBITDA	202.19	17.00	12.28	14.66	17.62	18.4
EV/Revenue	0.08	0.12	0.11	0.20	0.24	0.3
Earnings yield	-6.9%	1.1%	3.6%	3.9%	3.1%	2.86%
FCF yield	20.3%	10.2%	13.8%	4.6%	8.1%	7.69%

Ratio	FY22	FY23	FY24	FY25	FY26	TTM
LEVERAGE & SOLVENCY
Current ratio	1.08	1.00	0.98	0.94	0.88	0.88
Quick ratio	0.57	0.52	0.56	0.50	0.49	0.49
Debt / equity	-8.19	-1.75	-1.75	-3.36	-3.45	-3.45
Debt / assets	13.2%	11.9%	12.4%	17.6%	17.4%	17.4%
Net debt / EBITDA	15.11	0.77	0.24	1.76	1.46	1.46
Interest coverage	-4.16	7.86	27.04	10.77	7.25	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY22	FY23	FY24	FY25	FY26	TTM
EFFICIENCY
Asset turnover	4.11	4.70	5.12	4.53	4.61	4.44
Receivables turnover	18.45	18.92	19.55	17.58	18.79	18.4
DSO (days)	20	19	19	21	19	20
DPO (days)	53	53	51	57	54	57
Cash conversion cycle	-2	-4	-7	-9	-10	-11
GROWTH (YoY)
Revenue growth	11.6%	13.0%	10.6%	-1.8%	14.2%	—
Net income growth	-252.5%	128.0%	226.8%	83.0%	9.8%	—
EPS growth	-262.5%	130.3%	238.8%	86.8%	11.2%	—
FCF growth	34.8%	-13.8%	37.7%	-43.0%	144.6%	—
PER SHARE ($)
EPS (diluted, TTM)	-3.39	1.03	3.48	6.50	7.23	7.26
Book value / share	-2.58	-11.65	-13.11	-11.59	-12.16	-11.54
Revenue / share	659.51	807.13	925.18	927.41	1072.78	1077.32
FCF / share	9.95	9.28	13.25	7.71	19.09	19.17
Cash / share	17.15	16.05	20.95	16.14	20.49	20.58
SHAREHOLDER RETURN & SCORES
Buyback yield	7.4%	8.7%	3.2%	0.0%	2.4%	2.42%
Altman Z-Score	4.32	5.06	5.38	4.73	5.09	5.1
Piotroski F-Score	5	8	6	6	8	7/9
Beneish M-Score	-2.84	-2.77	-2.60	-2.32	-2.80	-2.80

Model	Score	Zone	Note
Piotroski F-Score	7 / 9	Strong
Altman Z-Score	5.1	Safe (>2.99)	Safe
Income quality	3.03	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.80	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.79
Interest burden	0.86
Operating margin	1.0%
Asset turnover	4.61×
Financial leverage	-19.50×
= ROE	-61%

Growth Quality (live)	Value
Revenue stability	0.94
Earnings stability	0.57
Earnings persistence	0.96
Revenue CAGR 3y	7.4%
EPS CAGR 3y	91.6%
FCF CAGR 3y	24.3%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield2.42%

Dividend Yield0.81%

Total Shareholder Return3.29%cash yield

SBC / Revenue0.1%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
ABC	$36.1B	13.3	104%	0.9%	+2.9%	7/9	—
MCK	$117.2B	26.8	-148%	0.6%	+8.8%	8/9	+29.7%
HSIC	$9.6B	25.0	12%	2.7%	+6.5%	7/9	+39.3%
NTRA	$56.7B	-289.3	-13%	-8.9%	+37.8%	6/9	+117.9%
BSX	$64.3B	17.9	15%	16.7%	+13.5%	8/9	-54.6%
BDX	$52.2B	57.8	4%	7.6%	-2.6%	6/9	—
ARGX	$51.5B	29.6	47%	29.8%	+242.1%	5/9	—
EW	$49.9B	49.8	9%	13.9%	+14.6%	6/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

33 Analysts

Str Sell (0)Sell (0)Hold (15)Buy (18)Str Buy (0)

Mean Target (qtr)$275.2711 targets

Target vs. Price+8.3%last-quarter mean

Next Report2026-11-05street $2.95

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$255.87B	$257.40B / $255.04B	$10.78	$10.82 / $10.75	6
FY2026	$275.63B	$281.19B / $270.68B	$12.08	$12.45 / $11.70	10
FY2027	$265.80B	$266.98B / $264.93B	$12.54	$12.59 / $12.50	10

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$295.00	+16.1%	1
Last Quarter	$275.27	+8.3%	11
Last Year	$253.84	-0.1%	31
All Time	$180.58	-28.9%	64

Rolling mean of published targets vs. last close $254.06. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B-

DCF

5/5

ROE

1/5

ROA

4/5

Debt/Eq

1/5

P/E

2/5

P/B

1/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

CAH +67.3% vs S&P 500 +15.9% — spread +51.4pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$232.07	+21.99	+9.48%	Above
SMA 50	$233.99	+20.07	+8.58%	Above
SMA 200	$218.95	+35.11	+16.04%	Above
EMA 9	$243.30	+10.76	+4.42%	Above
EMA 21	$237.05	+17.01	+7.18%	Above
EMA 50	$233.27	+20.79	+8.91%	Above
EMA 200	$216.11	+37.95	+17.56%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +7521 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%100

Momentum 25%100

Volume 20%75

Volatility 10%100

Patterns 15%50

This Week100% bullishof 11 price-based votes

4 Weeks Ago18%+82 pts since

12 Weeks Ago27%+73 pts since

ReadImprovingweek-over-week trajectory

Price vs SMA 20$232.07

Price vs SMA 50$233.99

Price vs SMA 200$218.95

EMA 9/21 Cross243.3/237.1

SMA 50/200Golden

ADX DirectionADX 22

Supertrend$236

Parabolic SAR$228

SMA Slope1.460

RSI74.3

Stochastic K/D98/96

StochRSI K/D100/99

Williams %R-4

CCI177

TSI vs Signal25.1

CMO48.6

ROC11.28%

OBV SignalAccum

Chaikin MF-0.040

MFI81

Force Index4M

Elder Ray Bull18.51

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 96

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$252.33 / $255.38 / $257.06	S1 / S2	$250.65 / $247.60
Bollinger (20,2)	$210.83 – $253.32	Squeeze	Off
52-wk range	$151.04 – $257.70	Off 52-wk high	-1.4%
ATR (14)	$5.78 (2.3%)	Historical vol	24.4%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+4.1%Jan90%

+2.0%Feb65%

-0.6%Mar43%

-0.8%Apr40%

+0.3%May55%

-0.3%Jun40%

+1.6%Jul65%

-1.9%Aug40%

-0.3%Sep35%

+2.3%Oct65%

+3.1%Nov70%

-0.3%Dec45%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	CAH	S&P 500
Weekly volatility (σ, 1y)	4.52%	1.83%
Best / worst week (1y)	+19.3% / -6.6%	—
Max drawdown (5y, monthly)	-28.3%	—
1-week VaR (95%)	-6.1%	—
Beta (5y)	0.52	1.00

CAH EQUITY WEATHER (LIVE)PARTLY CLOUDY · +26

Trend+47

Momentum+78

Volume+23

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 511 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+26.3+36.6 vs industry

Trend+47.2+48.2 vs industry

Momentum+78.2+85.6 vs industry

Volume+22.9+7.9 vs industry

Reading	CAH	Medical - Distribution n=156	Healthcare n=5,272	All US symbols n=70,435
Overall	+26.3	-10.3	-24.0	-20.5
Trend	+47.2	-1.0	-25.6	-21.3
Momentum	+78.2	-7.4	-28.5	-15.8
Volume	+22.9	+15.0	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Jason M. Hollar Chief Executive Officer	$22.6M	91% equity+incentive
Aaron E. Alt Chief Financial Officer	$6.9M	86% equity+incentive
Deborah L. Weitzman Chief Executive Officer,	$6.1M	87% equity+incentive
Jessica L. Mayer Chief Legal and Compliance	$5.5M	86% equity+incentive
Stephen M. Mason Chief Executive Officer, Gl	$5.3M	85% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	62
Social	51
Governance	62
Composite ESG	58

Composite ESG Trend

Filed	8-K contents	Items
2026-10-01	Regulation FD; Exhibits	7.01,9.01
2026-08-11	Earnings Release; Regulation FD; Exhibits	2.02,7.01,9.01
2026-08-11	Material Agreement; Termination of Agreement; Financial Obligation; Ex	1.01,1.02,2.03,9.01
2026-08-05	Officer/Director Change	5.02
2026-04-30	Earnings Release; Regulation FD; Exhibits	2.02,7.01,9.01
2026-03-23	Officer/Director Change; Regulation FD; Exhibits	5.02,7.01,9.01
2026-03-05	Departure/Election of Directors; Appointment of Officers	5.02
2026-02-05	Results of Operations and Financial Condition; Regulation FD Disclosur	2.02,7.01,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2021 to 2026
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-11-05 to 2026-08-11
Analyst estimates	dim/forward_estimates	3 rows · 2026-06-30 to 2027-06-30
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	114 rows · 1998 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-08-18 to 2026-08-19
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2026-01-21 to 2026-04-29
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Cardinal Health, Inc. (CAH)

Cardinal Health, Inc. (CAH)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Cardinal Health, Inc. (CAH)

Institutions holding — 12 quarters

Cardinal Health, Inc. (CAH)

Monthly Net Insider Flow (000 shares)

Signal Summary

Cardinal Health, Inc. (CAH)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding CAH — quarterly

Institutional Put/Call — quarterly

Cardinal Health, Inc. (CAH)

Where CAH Trades in the Dark

Cardinal Health, Inc. (CAH)

3.8 · Employees (SEC filings)

Cardinal Health, Inc. (CAH)

Cardinal Health, Inc. (CAH)

Cardinal Health, Inc. (CAH)

Balance Sheet — Full

Cash Flow Statement — Full

Cardinal Health, Inc. (CAH)

Cardinal Health, Inc. (CAH)

Cardinal Health, Inc. (CAH)

Cardinal Health, Inc. (CAH)

Street Price Target — Trajectory

Third-Party Composite Rating

Cardinal Health, Inc. (CAH)

Cardinal Health, Inc. (CAH)

Family Scores (site weights)

Cardinal Health, Inc. (CAH)

Cardinal Health, Inc. (CAH)

Cardinal Health, Inc. (CAH)